Comparative Study of Three Different Brands of Doxycycline Capsules Available in Karachi

Safila Naveed^*, Nimra Waheed

Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan.

DOI: 10.4236/oalib.1100458                

Abstract

Doxycycline (DOX) is lipophilic and synthetic derivative of tetracycline. DOX is a bacteriostatic agent that is active against gram-positive and gram-negative aerobic and anaerobic bacteria, Mycoplasmas, Chlamydiae, Rickettsiae, and some Protozoa. It inhibits the protein synthesis by restricting the binding of RNA to 30S ribosomal subunit. It is used for inflammatory conditions; periodontitis and acute coronary syndromes, variety of cancers, pulmonary fibrosis, emphysema, asthma, acute lung injury and for prophylaxis of malaria. The aim of this study is to evaluate the pharmaceutical equivalence of the three different brands of doxycycline capsules available in Karachi, Pakistan. For this purpose three different brands of doxycycline capsules (100 mg) were randomly selected from the local market using probability tools and evaluated for quality control parameters which are weight variation, disintegration and dissolution tests specified by BP/USP (British and United state Pharmacopoeia). Weight variation values of all brands comply with USP limits. Disintegration time for all brands was within 15 minutes also complying with the USP specification. All brands exhibited more than 80% drug release within 20 minutes. The present outcomes suggest that all the three brands of doxycycline capsule available in Karachi meet the USP specification for quality control analysis.

Keywords

Doxycycline, Dissolution, Disintegration, Weight Variation, Available Brands

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	McEvoy, G. (editor) (2008) AHFS Drug Information. American Society of Health-System Pharmacists, Inc., Bethesda. (Tetracyclines)
[2]	Abu-Basha, E.A., Idkaidek, N.M. and Hantash, T.M. (2006) Pharmacokinetics and Bioavailability of Doxycycline in Ostriches (Struthio camelus) at Two Different Dose Rates. Journal of Veterinary Science, 7, 327-332. http://dx.doi.org/10.4142/jvs.2006.7.4.327
[3]	Rieckmann, K.H., McNamara, J.V., Willerson, D., Kass, L., Frischer, J. and Carson, P.E. (1971) Effects of Tetracycline against Chloroquineresistant and Cloroquine-Sensitive Plasmodium falcuparum. The American Journal of Tropical Medicine and Hygiene, 20, 811-815.
[4]	Clyde, D.F., DuPont, H.L. and Hornick, R.B. (1971) Antimalarial Effects of Tetracyclines in Man. The Journal of Tropical Medicine and Hygiene, 74, 238-242.
[5]	Clark Jr., J.M. and Chang, A.Y. (1965) Inhibitors of the Transfer of Amino Acids from Aminoacyl Soluble Ribonucleic Acid to Proteins. The Journal of Biological Chemistry, 240, 4734-4739.
[6]	Saikali, Z. and Singh, G. (2003) Doxycycline and Other Tetracyclines in the Treatment of Bone Metastasis. Anticancer Drugs, 14, 773-778. http://dx.doi.org/10.1097/00001813-200311000-00001
[7]	Bryskier, A. (2005) Tetracyclines. In: Bryskier, A., Ed., Antimicrobial Agents. Antibacterials and Antifungals, ASM Press, Washington DC, 642-651.
[8]	Sagar, J., Sales, K., Dijk, S. and Taanman, J. (2009) Alexander Seifalian, and Mark Winslet. Does Doxycycline work in Synergy with Cisplatin and Oxaliplatin in Colorectal Cancer? World Journal of Surgical Oncology, 7, 2. http://dx.doi.org/10.1186/1477-7819-7-2
[9]	Beringer, P.M., Owens, H., Nguyen, A., Benitez, D., Rao, A. and D’Argenio, D.Z. (2012) Pharmacokinetics of Doxycycline in Adults with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 56, 70-74. http://dx.doi.org/10.1128/AAC.05710-11
[10]	Mohammadi, Z. and Abbott, P.V. (2009) On the Local Applications of Antibiotics and Antibiotic-Based Agents in Endodontics and Dental Traumatology. International Endodontic Journal, 42, 555-567. http://dx.doi.org/10.1111/j.1365-2591.2009.01564.x
[11]	Tan, K.R., Magill, A.J., Parise, M.E. and Arguin, P.M. (2011) Doxycycline for Malaria Chemoprophylaxis and Treatment: Report from the CDC Expert Meeting on Malaria Chemoprophylaxis. The American Journal of Tropical Medicine and Hygiene, 84, 517-531. http://dx.doi.org/10.4269/ajtmh.2011.10-0285
[12]	Valentín, S., Morales, A., Sánchez, J.L. and Rivera, A. (2009) Safety and Efficacy of Doxycycline in the Treatment of Rosacea. Clinical, Cosmetic and Investigational Dermatology, 2, 129-140.
[13]	FDA.gov (homepage on the Internet) Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) (updated 2009 Jan 23; cited 2009 Feb 26). http://www.fda.gov/cder/orange/default.htm
[14]	http://www.chemspider.com/Chemical-Structure.10482106.html
[15]	Jones, B.E. (2004) Capsule Standards, Chapter 13: Pharmaceutical Capsules. 2nd Edition, Pharmaceutical Press RPS Publishing, London, 241-250.